IAVI’s Vaccine Design and Development Lab

generates and develops innovative HIV and emerging infectious diseases vaccine candidates to address global public health needs.

Innovative vaccine research and development in Brooklyn, New York

IAVI’s Vaccine Design and Development Laboratory (DDL) is located at the bioscience center (BioBAT) in the historic Brooklyn Army Terminal. Since its founding in 2008 the DDL has become one of the world’s leading viral vector vaccine research and development labs, known for innovation and generation of novel vaccine design concepts.

The DDL executes work across multiple phases of vaccine development including early research needed for vaccine design, preclinical evaluation of vaccine candidates, and preparation of the most promising candidates for transition to a vaccine manufacturer. Biosafety Level (BSL) 2 laboratories are outfitted for molecular cloning, cell culture, virology, protein chemistry, and immunology research.

The DDL aims to translate scientific discoveries into affordable, globally accessible public health solutions

- HIV vaccine development
  HIV prevention remains an urgent state, national, and global need, and a vaccine will be needed to end HIV as a public health problem of global importance.

- Solutions to public health threats from emerging infectious diseases (EIDs)
  The DDL leverages its HIV vaccine development experience to advance vaccines for EIDs. In 2018, IAVI expanded into research on vaccine candidates to prevent disease caused by Lassa virus and Marburg virus. With the emergence of COVID-19 in early 2020, DDL researchers have been working on SARS-CoV-2 vaccine candidates. Most recently, the team has added Sudan Ebola virus to their EID vaccine platform. The U.S.

- Centers for Disease Control and Prevention has classified Lassa virus, Marburg virus, and Sudan Ebola virus as high-priority agents that pose a risk to national security. They have epidemic and bio-weapon potential and a high case fatality rate.

- Development of innovative technologies to address future outbreaks faster
  The DDL, IAVI, and partners are working to develop processes to enable cost-effective, flexible manufacturing of vaccine stockpiles to ensure rapid response during outbreaks.

Pivotal work at the DDL has led to important progress in HIV and EID vaccine research

- Investigation and advancement of viral vector technology for delivering HIV vaccines.
- Development of the vesicular stomatitis virus (VSV) as a vector platform to deliver vaccine immunogens derived from serious pathogens including HIV, Lassa fever, Marburg virus, Sudan Ebola virus, and SARS coronavirus 2.
- Contributions to identification of certain broadly neutralizing antibodies now being tested to prevent and treat HIV infection.
- Identification of an HIV envelope protein that has been used extensively for HIV structural studies and development of investigational vaccines.

The DDL is an anchor tenant in the BioBAT and is helping to fulfill the BioBAT vision of advancing life sciences in New York City.
The DDL has a highly experienced staff and broad capabilities

The DDL has a staff more than 25 highly experienced professionals, many of whom developed their expertise in different areas of the biopharmaceutical industry. IAVI senior leaders closely engaged in programs at the DDL also have past experience in leadership roles in the successful development of the Zaire Ebola virus vaccine during the 2014-16 outbreak.

The collective and broad experience of the IAVI organization, especially the DDL, is enabling rapid advancement of IAVI’s VSV-vectored vaccine candidate to prevent the pandemic coronavirus disease that emerged in 2019. This experience spans preclinical research, vaccine manufacturing, regulatory agency approvals, Phases I-III clinical trials, and product licensure.

IAVI partners with the State University of New York (SUNY) Downstate Medical Center Department of Comparative Medicine, where IAVI scientists conduct animal studies. Since 2006, the IAVI certified and/or licensed veterinary technicians working at the SUNY site have conducted 90 studies to assess vaccine safety, study immune responses to vaccination, and evaluate vaccine efficacy.

### IAVI’s VSV-vectored vaccine candidates

<table>
<thead>
<tr>
<th>Clinical development</th>
<th>Preclinical development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lassa fever virus*</td>
<td>HIV</td>
</tr>
<tr>
<td>Sudan Ebola virus*</td>
<td></td>
</tr>
<tr>
<td>SARS coronavirus 2 (2019)**</td>
<td></td>
</tr>
<tr>
<td>Marburg virus*</td>
<td></td>
</tr>
</tbody>
</table>

*Technology licensed from the Public Health Agency of Canada. Partners: Batavia Biosciences; George Washington University; KAVI-Institute of Clinical Research (Kenya); Kenema Government Hospital (Sierra Leone); La Jolla Institute for Immunology; LEAP4WA partners; MRC/UVRU and LSHTM Uganda Research Unit; National Public Health Institute of Liberia; Project San Francisco/Center for Family Health Research (Rwanda); Ragon Institute of MIT, MGH, and Harvard; Tulane University; University of Texas Medical Branch, Viral Hemorrhagic Fever Consortium.

**Previous funding received from Merck & Co., Inc. and the Biomedical Advanced Research and Development Authority (BARDA), and the Coalition for Epidemic Preparedness Innovations (CEPI).

---

The DDL regularly trains the next generation of scientific research interns from NYC-based institutions, some of whom have been hired as IAVI researchers.

### DDL funders

Work at the DDL is supported by the National Institutes of Health (NIH), the NIH National Institute of Allergy and Infectious Diseases (NIAID), the Government of Japan, the Defense Threat Reduction Agency (DTRA), the Biomedical Advanced Research and Development Authority (BARDA), and the Coalition for Epidemic Preparedness Innovations (CEPI).

---

IAVI gratefully acknowledges the generous support provided by the following major funders:

As of January 2024

---

IAVI gratefully acknowledges the generous support provided by the following major funders:

As of January 2024

---

Follow us

iavi.org
info@iavi.org
Go to iavi.org/subscribe to receive our updates